findmyKOL
Clinical trialNCT06246149RecruitingPhase 3Interventional

Adjuvant Tebentafusp in High Risk Ocular Melanoma

SponsorEuropean Organisation for Research and Treatment of Cancer - EORTCEnrollment290Uveal Melanoma
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

At least 50% of patients with high-risk primary uveal melanoma will develop a recurrence following treatment of the primary tumour. Observation is currently the standard of care in the non-metastatic setting. Tebentafusp is the first agent proven to improve overall survival in patients with metastatic uveal melanoma in a randomized trial. Based on the results in the advanced setting, it is hypothesized that treatment with tebentafusp may reduce the risk of development of disease recurrence.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

15 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Belgium
  • Cliniques Universitaires Saint-Luc

    Brussels, Belgium

    Recruiting
France
  • Centre Antoine Lacassagne

    Nice, France

    Recruiting
  • Institut Curie - Hôpital de Paris

    Paris, France

    Recruiting
Germany
  • Charite - Universitaetsmedizin Berlin - Campus Benjamin Franklin

    Berlin, Germany

    Recruiting
  • Universitaets Krankenhaus Eppendorf - Universitaetsklinikum Hamburg-Eppendorf Ke - University Cancer Center

    Hamburg, Germany

    Recruiting
  • Universitaetsklinikum Heidelberg - Frauenklinik / Hautklinik

    Heidelberg, Germany

    Recruiting
Netherlands
  • Leiden University Medical Centre

    Leiden, Netherlands

    Recruiting
  • Erasmus Mc

    Rotterdam, Netherlands

    Recruiting
Poland
  • Maria Sklodowska-Curie Memorial Cancer Centre - Maria Sklodowska-Curie National Research Institute of Oncology

    Warsaw, Poland

    Recruiting
Spain
  • Institut Catala D'Oncologia - Ico L'Hospitalet - Hospital Duran I Reynals (institut Catala D'Oncologia)

    L'Hospitalet de Llobregat, Spain

    Recruiting
  • Hospital Clinico Universitario de Valladolid

    Valladolid, Spain

    Recruiting
Sweden
  • Sahlgrenska Universitetssjukhuset

    Gothenburg, Sweden

    Recruiting
United Kingdom
  • the Clatterbridge Cancer Center Nhs Foundation Trust - Clatterbridge Cancer Center - Liverpool

    Liverpool, United Kingdom

    Recruiting
  • East and North Hertfordshire Nhs Trust - Mount Vernon Hospital

    Northwood, United Kingdom

    Recruiting
United States
  • Northwell Health -Center for Advanced Medicine

    Lake Success, New York, United States

    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Tebentafusp →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
11 Nov 2024
Primary completion
30 Nov 2032
Completion
30 Nov 2032
Last update posted
30 Jun 2026
Registered enrollment
290
Registry id
NCT06246149
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.